Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jason Karp Hates MannKind Corporation (MNKD), Likes NCR Corporation, International, Ltd. (ADR) (CTRP)

According to CNBC, Tourbillon Capital’s Jason Karp is betting on a decline of MannKind Corporation (NASDAQ:MNKD) shares. “Only in a frothy, retail-driven (and now Tweet-driven) market can a stock like MannKind exist with a $4.3 BILLION valuation and in our view no clear prospects of revenue… While Exubera has previewed what will happen with Afrezza, the market has had a way of ignoring this drug’s past failures until it actually launches…When and if this happens, we believe that MannKind will ultimately trade down 90% to a value around $500 million or $1/share. ” the letter said.

Jason Karp - Tourbillon Capital Partners

Jason Karp is bearish on MannKind Corporation (NASDAQ:MNKD) but he recently shared two long-term long investment ideas in two different investment conferences. The first stock he likes is NCR Corporation (NYSE:NCR). He held a $90 million call option on NCR shares at the end of March. NCR shares haven’t moved since his presentation, so you can follow his best idea without paying him anything.

“So my pitch today is NCR Corporation (NYSE:NCR). Most people think of this as the old National Cash Register company. This company is over 100 years old. Most people think of it as an ATM company that is just in the hardware business. In fact, most of NCR Corporation (NYSE:NCR) today is driven by their software business. And our contention is that this is in fact a rapidly growing software company inside of a cheap hardware company that no one’s really paying attention to. Our target price is up roughly 150% from here over the next 3 years,” said Jason Karp.

The second stock he is very bullish about is International, Ltd. (ADR) (NASDAQ:CTRP). Tiger cubs Stephen Mandel, Philippe Laffont, and Lee Ainslie initiated brand new positions in the stock during the first quarter. This stock is up around 30% since Karp’s presentation at the Ira Sohn Conference. Based on his predictions, it isn’t too late to monkey his bet on International, Ltd. (ADR) (NASDAQ:CTRP). “This is one of the best, highest probability growth names on the planet over the next decade. It’s a $7.5 billion company with $800 million in cash. It has an excellent management team. We actually think the long-term target on this stock next couple of years is a 3 to 4 bagger, so this is a big idea,” said Jason Karp.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!